Kreshnik Zejnullahu, MD

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
Address533 Parnassus Avenue, #001
San Francisco CA 94117
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of California San Francisco, San Francisco, CA07/2017Internal Medicine Residency
    University of Massachusetts Medical School, Worcester, MAM.D.05/2014Doctor of Medicine
    Bowdoin College, Brunswick, MEB.A.06/2005Biology

    Collapse Overview 
    Collapse Global Health Equity

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mycoplasma pneumoniae-Induced Rash and Mucositis in a Previously Healthy Man: A Case Report and Brief Review of the Literature. Open Forum Infect Dis. 2020 Oct; 7(10):ofaa437. Gandelman JS, Kim EY, Grzegorczyk AM, Zejnullahu K, Edson RS. PMID: 33094121; PMCID: PMC7568429.
      View in: PubMed   Mentions: 3  
    2. Off Trail, On Track: an Exercise in Clinical Reasoning. J Gen Intern Med. 2019 10; 34(10):2282-2287. Zejnullahu K, Santhosh L, Mourad M, Connor DM. PMID: 31270781; PMCID: PMC6816762.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 12; 15(6):733-741.e1. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. PMID: 28655452.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    4. Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy. Journal of Clinical Oncology. 2017 May 20; 35(15_suppl):e23055-e23055. Anantharaman AA, Friedlander FT, Welty WC, Zejnullahu ZK, Hough HJ, Edwards EM, Jendrisak JA, Lee LJ, Greene GS, Ontiveros OP, Graf GR, Rodriguez RA, Suraneni SM, Wang WY, Landers LM, Cooperberg CM, Carroll CP, Dittamore DR, Paris PP. .
      View in: Publisher Site   Mentions:
    5. Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy. Journal of Clinical Oncology. 2017 Feb 20; 35(6_suppl):110-110. Friedlander FT, Anantharaman AA, Welty WC, Zejnullahu ZK, Hough HJ, Edwards EM, Jendrisak JA, Lee LJ, Greene GS, Ontiveros OP, Graf GR, Rodriguez RA, Suraneni SM, Wang WY, Landers LM, Cooperberg CM, Carroll CP, Dittamore DR, Paris PP. .
      View in: Publisher Site   Mentions:
    6. Approaches to minimize castration in the treatment of advanced prostate cancer. Urol Oncol. 2016 08; 34(8):368-74. Zejnullahu K, Arevalo MG, Ryan CJ, Aggarwal R. PMID: 26944450.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    7. Diffuse Alveolar Hemorrhage: Blood, Sweat and Tears. J Gen Intern Med. 2016 07; 31(7):812-3. Zejnullahu K, Khatami S, Manesh RS. PMID: 26892322; PMCID: PMC4907939.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. Elife. 2015 Jun 05; 4:e06907. Unni AM, Lockwood WW, Zejnullahu K, Lee-Lin SQ, Varmus H. PMID: 26047463; PMCID: PMC4478584.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansAnimalsCells
    9. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res. 2013 Jan 15; 73(2):834-43. Cortot AB, Repellin CE, Shimamura T, Capelletti M, Zejnullahu K, Ercan D, Christensen JG, Wong KK, Gray NS, Jänne PA. PMID: 23172312; PMCID: PMC3994895.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCells
    10. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A. 2012 Nov 20; 109(47):19408-13. Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. PMID: 23129625; PMCID: PMC3511085.
      View in: PubMed   Mentions: 183     Fields:    Translation:HumansCells
    11. Abstract 4833: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutics antibody cetuximab. Experimental and Molecular Therapeutics. 2012 Apr 15; 4833-4833. Yonesaka YK, Okamoto OI, Taroh TS, Zejnullahu ZK, Nishio NK, Fukuoka FM, Janne JP, Nakagawa NK. .
      View in: Publisher Site   Mentions:
    12. OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. European Journal of Cancer. 2011 Oct 1; 47:s10. Yonesaka YK, Zejnullahu ZK, Okamoto OI, Satoh ST, Cappuzzo CF, Souglakos SJ, Engelman EJ, Varella-Garcia VM, Nakagawa NK, Jänne JP. .
      View in: Publisher Site   Mentions:
    13. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011 Sep 07; 3(99):99ra86. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA. PMID: 21900593; PMCID: PMC3268675.
      View in: PubMed   Mentions: 294     Fields:    
    14. Abstract 251: Kinome-wide RNAi screen identification of synthetic lethal interactions in BRAF-mutant melanoma. Cellular and Molecular Biology. 2011 Apr 15; 251-251. Zejnullahu ZK, Wagenaar WT, Green GM. .
      View in: Publisher Site   Mentions:
    15. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene. 2010 Apr 22; 29(16):2346-56. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA. PMID: 20118985; PMCID: PMC2859699.
      View in: PubMed   Mentions: 102     Fields:    
    16. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010 Jan 19; 17(1):77-88. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA. PMID: 20129249; PMCID: PMC2980857.
      View in: PubMed   Mentions: 473     Fields:    
    17. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res. 2008 Nov 01; 14(21):6963-73. Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Jänne PA. PMID: 18980991; PMCID: PMC3227691.
      View in: PubMed   Mentions: 55     Fields:    
    18. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008 Jul 01; 14(13):4275-83. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA. PMID: 18594010; PMCID: PMC3025451.
      View in: PubMed   Mentions: 391     Fields:    
    19. Abstract 4958: Presence of amphiregulin autocrine-loop predicts sensitivity of EGFR wild type cancers to gefitinib and cetuximab. Clinical Research. 2008 May 15; 4958-4958. Yonesaka YK, Zejnullahu ZK, Homes HA, Johnson JB, Janne JP. .
      View in: Publisher Site   Mentions:
    20. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007 Dec 15; 67(24):11924-32. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA. PMID: 18089823.
      View in: PubMed   Mentions: 273     Fields:    Translation:HumansAnimalsCells
    21. C1-07: IPI-504, a novel HSP90 inhibitor is effective in EGFR T790M and Non-T790M Gefitinib-resistant Lung Cancer Cell Lines. Journal of Thoracic Oncology. 2007 Aug 1; 2(8):s361. Park PJ, Zhao ZF, Zejnullahu ZK, Normant NE, Engelman EJ, Johnson JB, Jänne JP. .
      View in: Publisher Site   Mentions:
    22. D2-07: Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors. Journal of Thoracic Oncology. 2007 Aug 1; 2(8):s396. Engelman EJ, Zejnullahu ZK, Mitsudomi MT, Hyland HC, Park PJ, Lindeman LN, Gale GC, Zhao ZX, Christensen CJ, Rogers RR, Cappuzzo CF, Mok MT, Lee LC, Bruce BJ, Cantley CL, Jänne JP. .
      View in: Publisher Site   Mentions:
    23. C7-07: Presence of amphiregulin autocrine-loop predicts in vitro sensitivity of EGFR wild type NSCLC and HNSCC cell lines to gefitinib and cetuximab. Journal of Thoracic Oncology. 2007 Aug 1; 2(8):s382. Yonesaka YK, Zejnullahu ZK, Homes HA, Johnson JB, Janne JP. .
      View in: Publisher Site   Mentions:
    24. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007 May 18; 316(5827):1039-43. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. PMID: 17463250.
      View in: PubMed   Mentions: 1925     Fields:    Translation:HumansAnimalsCells
    25. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest. 2006 Oct; 116(10):2695-706. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA. PMID: 16906227; PMCID: PMC1570180.
      View in: PubMed   Mentions: 194     Fields:    Translation:HumansAnimalsCells
    Kreshnik's Networks
    Concepts (114)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (11)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.